Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, PCI will purchase Humaneered (lenzilumab), for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
Lead Product(s): Lenzilumab,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Humaneered
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Humanigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2022